Nanoviricides (NNVC) Cash & Equivalents (2010 - 2026)

Nanoviricides has reported Cash & Equivalents for 17 years, with the latest figure at $3.2 million in Q1 2026.

• Quarterly Cash & Equivalents rose 28.53% year-over-year to $3.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.2 million (up 28.53% YoY) and the FY2025 annual result came in at $1.6 million, down 67.51% from the prior year.
• Cash & Equivalents fell to $3.2 million in Q1 2026 per NNVC's latest filing, from $5.2 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $15.6 million in Q1 2022 and troughed at $1.1 million in Q3 2025.
• A 5-year average of $6.7 million and a median of $5.2 million in 2025 frame the typical range for Cash & Equivalents.
• The widest YoY moves for Cash & Equivalents: up 30.13% in 2025, down 71.79% in 2025.
• Over 5 years, Cash & Equivalents stood at $11.4 million in 2022, then plunged by 54.39% to $5.2 million in 2023, then decreased by 23.88% to $4.0 million in 2024, then jumped by 30.13% to $5.2 million in 2025, then sank by 37.61% to $3.2 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $3.2 million, $5.2 million, and $1.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.